BioLife Cell Bank Sponsors Families of SMA Conference
Dallas, TX, June 20, 2013 --(PR.com)-- Continuing their commitment to children and families affected by spinal muscular atrophy (SMA), BioLife Cell Bank, Inc., attended the 2013 Annual SMA Conference June 13-16 in Anaheim, Calif. as a Silver sponsor.
For 24 years, Families of SMA (FSMA) has hosted this conference—the largest in the world for those affected by SMA, offering networking opportunities, workshops, kids’ programs and research updates. The conference brings together leading researchers with SMA-impacted families, offering a unique opportunity for interaction and information exchange.
BioLife was represented by Chief Executive Officer, John A. Carbona, Director of Research, Mindy Du, and their entire Scientific Advisory Board. “The FSMA organization continues to show their passion for curing this disease, and for the children and their families who must live with it daily,” said Carbona. “We recognize this as a significant opportunity—one to share updates and to develop relationships with scientists and patients alike, as we move forward with a common goal, ending SMA.”
Last August, BioLife, the leader in cryogenic storage of adipose (fat) tissue and adult mesenchymal stem and regenerative cells, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary products to provide control over cellular function, formed an exclusive research collaboration striving to produce new treatments for SMA. Intrexon was represented at the conference by their Human Therapeutics Division President and Senior Vice President, Dr. Jayson M. Rieger.
For more information about BioLife: 972-331-1905 or biolifecellbank.com.
About Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About BioLife
As part of their core business, BioLife Cell Bank, Inc. offers individuals a way to safely store their adipose (fat) tissue and/or their adipose-derived stem and regenerative cells--giving patients and physicians easy, multi-use access to cells and tissue for future cosmetic, reconstructive and regenerative therapies. Extracted via liposuction, tissue is sent to BioLife in a collection kit (validated to E.T.L. standards) where it is processed using proprietary technology and Cytori Therapeutics' products. Tissue is cryogenically preserved, and may be stored indefinitely. BioLife is registered with the FDA as a processing bank and complies with FDA regulations and guidance including current Good Tissue Practice (cGTP). BioLife is based in Dallas, Texas, at Forest Park Medical Center. For more information: biolifecellbank.com.
Contacts:
Corporate Contact:
John A. Carbona, 972-331-1905
Chief Executive Officer
jcarbona@biolifecellbank.com
or
Media Contact:
Kristin Laminack, 972-331-9626
Director, Marketing and Media
kristin@biolifecellbank.com
For 24 years, Families of SMA (FSMA) has hosted this conference—the largest in the world for those affected by SMA, offering networking opportunities, workshops, kids’ programs and research updates. The conference brings together leading researchers with SMA-impacted families, offering a unique opportunity for interaction and information exchange.
BioLife was represented by Chief Executive Officer, John A. Carbona, Director of Research, Mindy Du, and their entire Scientific Advisory Board. “The FSMA organization continues to show their passion for curing this disease, and for the children and their families who must live with it daily,” said Carbona. “We recognize this as a significant opportunity—one to share updates and to develop relationships with scientists and patients alike, as we move forward with a common goal, ending SMA.”
Last August, BioLife, the leader in cryogenic storage of adipose (fat) tissue and adult mesenchymal stem and regenerative cells, and Intrexon Corporation, a synthetic biology company that utilizes its proprietary products to provide control over cellular function, formed an exclusive research collaboration striving to produce new treatments for SMA. Intrexon was represented at the conference by their Human Therapeutics Division President and Senior Vice President, Dr. Jayson M. Rieger.
For more information about BioLife: 972-331-1905 or biolifecellbank.com.
About Spinal Muscular Atrophy
Spinal Muscular Atrophy (SMA) is an autosomal-recessive genetic disorder characterized by progressive weakness of the lower motor neurons. SMA is caused by a genetic defect in the SMN1 gene which codes SMN, a protein necessary for survival of motor neurons. SMA kills more infants than any other genetic disease in today's world.
About BioLife
As part of their core business, BioLife Cell Bank, Inc. offers individuals a way to safely store their adipose (fat) tissue and/or their adipose-derived stem and regenerative cells--giving patients and physicians easy, multi-use access to cells and tissue for future cosmetic, reconstructive and regenerative therapies. Extracted via liposuction, tissue is sent to BioLife in a collection kit (validated to E.T.L. standards) where it is processed using proprietary technology and Cytori Therapeutics' products. Tissue is cryogenically preserved, and may be stored indefinitely. BioLife is registered with the FDA as a processing bank and complies with FDA regulations and guidance including current Good Tissue Practice (cGTP). BioLife is based in Dallas, Texas, at Forest Park Medical Center. For more information: biolifecellbank.com.
Contacts:
Corporate Contact:
John A. Carbona, 972-331-1905
Chief Executive Officer
jcarbona@biolifecellbank.com
or
Media Contact:
Kristin Laminack, 972-331-9626
Director, Marketing and Media
kristin@biolifecellbank.com
Contact
BioLife Cell Bank
Kristin Laminack
972-331-1905
www.biolifecellbank.com
Kristin Laminack
972-331-1905
www.biolifecellbank.com
Contact
Categories